---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-031973"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2025-02-21T23:59:59+00:00"
generated_at: "2026-05-26T07:11:28.569583+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Centessa licenses LockBody platform to Genmab; $15M upfront, up to $230M per product milestones

## Summary
- Upfront payment of $15M from Genmab; option fees up to $15M for up to three undisclosed targets.
- Eligible for ~$230M in development, regulatory, and sales milestones per product plus tiered mid-single-digit royalties.
- Genmab to lead all R&D; may combine LockBody technology with Genmab's proprietary antibodies.
- LockBody platform enables conditional activation of cell killing in diseased tissue to improve therapeutic index.
- Multi-year research period; Genmab can terminate for convenience or on a target-by-target basis.

## SEC filing metadata
- accession: 0001193125-25-031973
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2025-02-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000119312525031973/0001193125-25-031973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000119312525031973/d894992d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-031973
- JSON: https://secwatch.observer/filing/0001193125-25-031973.json
- Plain text: https://secwatch.observer/filing/0001193125-25-031973.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.